---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-023806"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:28:31.032365+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NRXP amends $11M convertible note; $1.1M cash due Feb 12, then $400K/month through July

## Summary
- Third Amendment to $11.02M convertible note with Streeterville Capital executed Feb 9, 2024.
- Company to pay $1.1M cash on Feb 12, 2024; monthly $400K cash minimum from Feb 29 to July 31, 2024.
- During first three months, Streeterville cannot redeem above monthly minimum; after, up to $1M/month subject to cap.
- Company can pay monthly minimum in shares if Streeterville submits redemption notices; otherwise cash required.
- Outstanding balance after July 31, 2024 must be fully paid in cash by Aug 31, 2024.

## SEC filing metadata
- accession: 0001104659-24-023806
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/0001104659-24-023806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/tm246184d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-023806
- JSON: https://secwatch.observer/filing/0001104659-24-023806.json
- Plain text: https://secwatch.observer/filing/0001104659-24-023806.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. amended Amendment #3 to Convertible Promissory Note with Streeterville Capital, LLC valued at $1,100,000 (effective 2024-02-09).
  - Action: amendment
  - Counterparty: Streeterville Capital, LLC
  - Value: $1,100,000
  - Effective: 2024-02-09
  source text: On February 9, 2024 NRX Pharmaceuticals, Inc. (the “Company”) entered into Amendment #3 to Convertible Promissory Note (the “Third Amendment”), with Streeterville Capital, LLC (“Streeterville”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/0001104659-24-023806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.